Gastrointestinal amyloidosis occurs when misfolded proteins accumulate in the walls of the digestive tract, disrupting normal tissue structure and organ function. It can affect everything from the esophagus to the rectum, as well as the liver, and its symptoms overlap heavily with far more common conditions like inflammatory bowel disease and irritable bowel syndrome. That overlap is part of why diagnosing it remains genuinely difficult, even at major medical centers. The patterns it produces depend on which type of amyloid protein is involved, where in the gut it deposits, and how deeply it infiltrates the tissue layers.
How Amyloid Proteins Damage the Gut
Amyloidosis is not a single disease. It is a group of disorders in which the body produces abnormal proteins that fold into an insoluble shape and pile up outside of cells.1European Journal of Gastroenterology & Hepatology. Amyloidosis of the gastrointestinal tract and the liver: clinical context, diagnosis and management These misfolded proteins arrange themselves into stiff, sheet-like structures that wedge into tissue layers and gradually distort whatever organ they land in.2PubMed Central. Gastrointestinal amyloidosis: A focused review In the gastrointestinal tract, that means the deposits can settle into the mucosal lining, the deeper muscular layers, the nerve networks that coordinate gut movement, or the blood vessels feeding the bowel wall. The specific precursor protein that gets overproduced defines which “type” of amyloidosis a person has, and that distinction drives both prognosis and treatment.
The Main Subtypes and Their Prevalence
Several types of amyloidosis can affect the gut, but they do so at very different rates. Light chain amyloidosis, known as AL amyloidosis, is the most common form found in the GI tract. Among GI amyloidosis cases, lambda light chains account for roughly half, while kappa light chains make up a much smaller share. Hereditary transthyretin amyloidosis (ATTR) is the next most common, comprising about one in six cases. Secondary amyloidosis (AA), which arises from chronic inflammatory conditions like rheumatoid arthritis or longstanding infections, accounts for a smaller fraction.3The American Journal of Medicine. Gastrointestinal Amyloidosis: Patterns, Symptoms, and Diagnosis
These distinctions matter because each subtype has a different underlying cause. AL amyloidosis stems from an abnormal plasma cell clone in the bone marrow producing excess light chain fragments. ATTR amyloidosis involves a mutated or unstable transthyretin protein, normally made by the liver. AA amyloidosis is fueled by chronically elevated serum amyloid A protein during prolonged inflammation. Treatment is entirely different for each, so identifying the subtype is not academic bookkeeping; it directly changes what medications a patient receives.
Symptoms Across the Digestive Tract
The symptoms of GI amyloidosis are frustratingly nonspecific. Abdominal pain, nausea, early satiety, diarrhea, constipation, and unintentional weight loss all appear on the list, and every one of those can be caused by dozens of more common conditions. What makes the clinical picture distinctive is the combination and severity, and the fact that standard treatments for those symptoms often fail to help.
Diarrhea is one of the most common and debilitating complaints. It can become intractable, resisting the usual medications, and in some patients alternates unpredictably with periods of pseudo-obstruction, where the bowel essentially stops moving even though no physical blockage exists.4The Korean Journal of Gastroenterology. Intestinal Amyloidosis with Intractable Diarrhea and Intestinal Pseudo-obstruction This alternation between diarrhea and near-complete bowel stasis is a red flag that something beyond ordinary irritable bowel syndrome or infectious colitis is going on.
In hereditary ATTR amyloidosis, GI symptoms often stem from nerve damage as much as from direct tissue infiltration. Amyloid deposits can disrupt the autonomic nerves that coordinate the rhythmic contractions of the small bowel, leading to abnormal motility patterns consistent with a combined nerve-and-muscle disorder.5PubMed. Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis The result is erratic movement of food through the intestines: too fast in some segments, too slow in others, producing bloating, cramping, and malabsorption.
Beyond the gut itself, patients with AL amyloidosis frequently report fatigue, weakness, dizziness, and swelling in the legs, reflecting the disease’s systemic reach. Emotional impacts like anxiety, frustration, and depression are common as the illness limits physical and social functioning.
Bleeding and Vascular Fragility
One of the more alarming complications of GI amyloidosis is bleeding that seems to come out of nowhere. Amyloid fibrils have a tendency to accumulate around the blood vessels in the submucosa, the tissue layer just beneath the inner lining of the gut. This deposits weaken vessel walls, making them fragile and prone to spontaneous rupture.6PubMed Central. Light-Chain (AL) Amyloidosis as a Rare Cause of Upper Gastrointestinal Bleeding: A Case Report and Systematic Literature Review The bleeding can be slow and chronic, leading to iron-deficiency anemia that builds over months, or it can be sudden and severe.
Submucosal hematomas, essentially pockets of blood forming inside the bowel wall, are a recognized manifestation. The proposed mechanism is straightforward: vessel walls already weakened by amyloid deposits give way under normal blood pressure, and blood leaks into the surrounding tissue.7American Journal of Case Reports. An Unsusual Case of Lower Gastrointestinal Bleeding This vascular fragility also creates a practical problem for clinicians. Biopsies and endoscopic procedures carry a higher risk of bleeding and perforation in patients with amyloid-infiltrated tissue, a hazard that may not be apparent until after the procedure.8PubMed Central. A Case of Severe Post-Biopsy Bleeding and Perforation in Gastric Amyloidosis
When the Liver Is Involved
Amyloid deposits in the liver can produce a clinical picture that sends doctors down the wrong diagnostic path for months. The liver may enlarge dramatically, sometimes becoming palpable well below the rib cage, while blood tests show a cholestatic pattern, meaning markers of bile flow obstruction rise even though no stone or tumor is blocking the bile ducts.9PubMed Central. Hepatic Involvement as the Sole Presentation of Systemic Amyloid Light Chain (AL) Amyloidosis: A Diagnostic Challenge In some patients, the liver involvement is severe enough to cause full-blown portal hypertension with esophageal varices, a complication usually associated with cirrhosis.10PubMed. Huge hepatomegaly, jaundice and portal hypertension due to amyloidosis of the liver
What makes hepatic amyloidosis tricky is that imaging often fails to distinguish it from other infiltrative liver diseases. A large, homogeneously enhancing liver on a CT scan could be amyloidosis, but it could also be lymphoma, sarcoidosis, or several other conditions. In some cases, the liver is the sole organ showing clinical signs at the time of diagnosis, with no obvious GI symptoms to suggest amyloidosis as a possibility. These patients tend to undergo extensive workups for liver disease before anyone considers amyloid as the cause.
What Endoscopy Reveals
GI amyloidosis does not have a single signature appearance on endoscopy, which is part of why it gets missed. The findings vary widely: friable mucosa that bleeds easily when touched, erosions, frank ulcers, submucosal hematomas, and mucosal thickening with polypoid bumps.11PubMed Central. Clinical and endoscopic manifestations of gastrointestinal amyloidosis: a case series In the small bowel, endoscopic examination sometimes shows a fine granular texture of the mucosa, thickened folds, or multiple polypoid protrusions.12PubMed. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein
None of these findings are unique to amyloidosis. Friable mucosa with erosions can look identical to Crohn’s disease. Polypoid protrusions raise suspicion for lymphoma or carcinoma. Submucosal hematomas might suggest a coagulopathy or vascular malformation. The endoscopist has to think of amyloidosis as a possibility and take biopsies in the right way to detect it. Without that clinical suspicion, the tissue samples may be interpreted as showing nonspecific inflammation, and the diagnosis is delayed.
The Diagnostic Challenge and Why Misdiagnosis Is Common
GI amyloidosis is one of those diseases where the diagnosis often gets made late because nobody thought to look for it. The colonic deposits can mimic inflammatory bowel disease, colorectal cancer, ischemic colitis, and collagenous colitis.13Advances in Clinical and Experimental Medicine. Intestinal amyloidosis: Clinical manifestations and diagnostic challenge Patients may carry an incorrect diagnosis of Crohn’s disease or ulcerative colitis for years, receiving immunosuppressive medications that do nothing for their actual condition and may worsen their overall health.
A few clinical clues should raise suspicion. Weight loss that is out of proportion to the apparent severity of the GI symptoms, diarrhea that does not respond to standard treatments, unexplained GI bleeding in a patient with a known plasma cell disorder or chronic inflammatory disease, and autonomic symptoms like orthostatic dizziness or early satiety alongside bowel complaints all suggest that something beyond a common GI disorder is at work. In patients already known to have AL amyloidosis affecting the heart or kidneys, GI involvement should be actively looked for rather than assumed absent.
Biopsy, Congo Red, and Confirming the Diagnosis
A definitive diagnosis of amyloidosis requires tissue. The classic histological test uses Congo red stain: when amyloid deposits absorb the dye and are viewed under polarized light, they display a characteristic apple-green birefringence.14PubMed. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis This test has been the gold standard for decades, though it has well-known limitations. Small deposits can be missed, and the staining is technically sensitive to how the tissue was fixed and processed. A negative Congo red stain does not rule out amyloidosis if the clinical picture is convincing.
Where to biopsy is an important practical question. Abdominal fat pad aspiration is a minimally invasive option and is often the first tissue test performed, but its sensitivity for GI-related amyloidosis is not as high as direct GI biopsy. In one study of patients with rheumatoid arthritis, GI biopsy results correlated strongly with kidney biopsy results, while fat pad biopsy results did not track as reliably.15PubMed. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis Combining biopsy sites improves sensitivity considerably. When both skin fat and rectal mucosal biopsies were performed in patients with AL amyloidosis, the combined sensitivity reached about 99%.16PLOS ONE. Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement
That said, any biopsy in a patient with known or suspected GI amyloidosis carries heightened risk. The same vascular fragility that causes spontaneous bleeding also makes post-biopsy bleeding more likely, and perforation has been reported even from routine endoscopic biopsies of amyloid-infiltrated tissue.8PubMed Central. A Case of Severe Post-Biopsy Bleeding and Perforation in Gastric Amyloidosis This is not a reason to avoid biopsy, but it means that clinicians should be prepared for complications and weigh the risks carefully, especially in patients with borderline coagulation.
Typing the Amyloid with Mass Spectrometry
Finding amyloid in tissue is only half the job. Identifying exactly which protein is forming the deposits is critical for choosing the right treatment, and historically this step has been unreliable. Older antibody-based typing methods sometimes gave ambiguous or outright wrong results because different amyloid proteins can look similar under standard immunohistochemistry.
Mass spectrometry-based proteomics has largely solved this problem. The technique works by laser-dissecting the amyloid deposits out of a tissue sample and then running the extracted proteins through a mass spectrometer that identifies them by their molecular weight and fragmentation pattern. In a study validating this approach across 50 well-characterized amyloidosis cases, the method identified the amyloid type with perfect accuracy in the training set and near-perfect accuracy in an independent validation set of cardiac amyloidosis cases.17PubMed. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens A large review of over 16,000 samples at a single referral center confirmed the reliability and clinical utility of the technique using both paraffin-embedded tissue and unfixed fat aspirate specimens.18Mayo Clinic Proceedings. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples
The practical impact is significant. A clinical assay applied to subcutaneous fat aspirates over a four-year period classified amyloidosis with about 90% sensitivity and identified a range of subtypes, including light chain, transthyretin, serum amyloid A, gelsolin, and lysozyme forms.19Haematologica. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics Before mass spectrometry became available for clinical use, mistyped amyloidosis led to patients receiving the wrong treatment, sometimes for years. An AL patient treated as though they have ATTR, or vice versa, gains nothing and loses precious time.
What Imaging Can and Cannot Tell You
Cross-sectional imaging with CT or MRI is usually part of the workup for GI amyloidosis, but the findings tend to be nonspecific. On CT, amyloid deposits may appear as soft-tissue masses with density similar to skeletal muscle, sometimes containing calcifications. In some patients, amyloidosis shows up as diffuse thickening of the bowel wall or an infiltrative mass encasing the mesentery.20Journal of Clinical Imaging Science. Mesenteric Amyloidosis: Radiologic Imaging with Pathologic Correlation On MRI, amyloid involvement of the GI system generally appears as low signal intensity on certain sequences, which can help narrow the differential but is far from diagnostic on its own.
PET/CT using the standard radiotracer has been explored, but its sensitivity for systemic GI amyloidosis appears limited. One study found uptake in all patients with localized amyloidosis but no uptake in systemic forms, a distinction that could actually be useful if confirmed in larger series.20Journal of Clinical Imaging Science. Mesenteric Amyloidosis: Radiologic Imaging with Pathologic Correlation In practice, imaging helps with staging the extent of disease, identifying complications like perforation or obstruction, and ruling out alternative diagnoses, but it cannot confirm amyloidosis. That still requires tissue.
CT findings in GI amyloidosis can also mimic enterocolitis, creating yet another avenue for misdiagnosis. A contrast-enhanced CT scan showing bowel wall thickening and mucosal enhancement in a patient with diarrhea and abdominal pain looks indistinguishable from infectious or inflammatory enterocolitis.21PubMed Central. Gastrointestinal amyloidosis presenting as enterocolitis on abdominal CT scan
Managing GI Symptoms
Treatment of GI amyloidosis has two layers: addressing the underlying amyloid-producing disorder and managing the GI symptoms themselves. The systemic treatment is subtype-specific. AL amyloidosis is treated with chemotherapy targeting the abnormal plasma cell clone. ATTR amyloidosis now has several targeted therapies, including drugs that stabilize the transthyretin protein or silence the gene producing it. AA amyloidosis is managed by controlling the underlying inflammatory disease.22PubMed Central. Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations
Regardless of subtype, supportive care for GI symptoms is a major part of management. Standard anti-nausea medications are used for nausea and vomiting, while anti-diarrheal agents are often needed for chronic diarrhea. For the dysmotility and early satiety that plague many patients, prokinetic medications have been tried with limited success. One prokinetic used to stimulate gastric emptying showed some benefit in an ATTR patient with delayed stomach emptying.23Haematologica. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
Nutritional support turns out to be one of the most important interventions. Malabsorption from damaged small bowel mucosa, reduced oral intake from nausea and early satiety, and chronic diarrhea all conspire to push patients toward significant weight loss and nutritional deficiency. Systematic reviews emphasize that nutritional intervention is essential across all subtypes of GI amyloidosis and that standardized approaches to nutritional support can meaningfully improve quality of life.22PubMed Central. Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations Some patients eventually require parenteral nutrition when the gut can no longer absorb enough calories and nutrients on its own.
Hereditary Forms and the Problem of Recognition
Hereditary transthyretin amyloidosis deserves special mention because its GI manifestations are common across all known genetic variants of the disease, yet they are among the least recognized. Early symptoms like alternating diarrhea and constipation, unexplained weight loss, and nausea are easily attributed to functional bowel disorders or dietary issues, especially in younger patients who do not fit the typical profile for amyloidosis. The GI complaints often precede the more dramatic cardiac and neurological features by years, which means there is a window where the correct diagnosis could be made but rarely is.
Because the GI symptoms are so nonspecific, patients with hereditary ATTR amyloidosis frequently get misdiagnosed with irritable bowel syndrome, celiac disease, or gastroparesis before the true cause is identified. Awareness of the family history is the single most useful clue. If a patient has unexplained GI dysmotility and a family member with cardiomyopathy or polyneuropathy, ATTR amyloidosis should be on the list of possibilities.
Procedural Risks in Amyloid-Infiltrated Tissue
The increased tissue fragility caused by amyloid deposits creates a clinical catch-22. Diagnosing the disease requires biopsy, but biopsy of amyloid-infiltrated tissue carries elevated risks of both bleeding and perforation. The amyloid deposits weaken the structural integrity of the bowel wall at the same time they make the blood vessels within it more likely to bleed when cut or sampled. Endoscopists working with patients suspected of having GI amyloidosis sometimes use smaller biopsy forceps, take fewer samples, or focus on sites where the mucosa appears less friable. There is no established protocol for reducing procedural risk in these patients, and the decision often comes down to the clinician’s judgment about how much tissue fragility is present based on the endoscopic appearance.
For patients who have already been diagnosed with systemic amyloidosis and develop new GI symptoms, the question of whether to biopsy again or to presume GI involvement based on the clinical picture is a real one. Repeat endoscopy with biopsy adds diagnostic certainty but at a cost that may not always be justified, particularly in patients with advanced disease where the management would not change regardless of what the biopsy shows.